Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C

Journal of Viral Hepatitis

Volumn 19, Issue SUPPL. 1, 2012, Pages 3-6

  Degasperi, E ^a   Aghemo, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

antiviral therapy; eligibility; hepatitis C; peginterferon; ribavirin; sustained virological response

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ALGORITHM; ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; DISEASE SEVERITY; ERADICATION THERAPY; HEPATITIS C; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ELIGIBILITY DETERMINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84855705866     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01517.x     Document Type: Article

References (20)

1. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5): 1303-1313. (Pubitemid 34465173)
2. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45 (3): 579-587. (Pubitemid 46453759)
3. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
4. Alazawi W, Cunningham M, Dearden J, Foster GR,. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32 (3): 344-355.
5. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52 (5): 652-657.
6. Colloredo G, Guido M, Sonzogni A, Leandro G,. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39 (2): 239-244. (Pubitemid 36920560)
7. Alberti A, Chemello L, Benvegnu L,. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 17-24. (Pubitemid 30002686)
8. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38 (3): 257-265. (Pubitemid 36286537)
9. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB,. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39 (1): 2-17. (Pubitemid 46039435)
10. Tsui JI, Vittinghoff E, Shlipak MG, et al. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167 (12): 1271-1276. (Pubitemid 46998498)
11. Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010; 116 (23): 4926-4233.
12. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007; 120 (12): 1034-1041. (Pubitemid 350166219)
13. Cheng WS, Roberts SK, McCaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010; 53 (4): 616-623.
14. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O,. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol 2007; 42 (2): 247-255.
15. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43 (3): 425-433. (Pubitemid 41111423)
16. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138 (1): 108-115.
17. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138 (1): 116-122.
18. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361 (6): 580-593.
19. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49 (4): 528-536.
20. Volk ML, Tocco R, Saini S, Lok AS,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50 (6): 1750-1755.